Skip to content

The Effect of Honey on Xerostomia and Oral Mucositis

A Randomized Control Trial for the Effect of Honey on Radiotherapy Induced Xerostomia and Oral Mucositis in Patients With Head and Neck Cancers

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01465308
Acronym
AC-H
Enrollment
72
Registered
2011-11-04
Start date
2011-08-31
Completion date
2014-10-31
Last updated
2014-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancer

Keywords

head and neck cancer, radiotherapy induced xerostomia, radiotherapy induced oral mucositis, RCT, symptom management

Brief summary

The purpose of this study is to determine whether the use of pure honey will help in the treatment of radiation induced xerostomia and oral mucositis (symptom management)

Detailed description

Radiation-induced mucositis is a normal acute side effect of radiotherapy treatment. Exposure of ionising radiation to oral, pharyngeal and laryngeal mucosa gives rise to radiation epithelitis towards the second and third weeks of conventional fractionated radiotherapy. Likewise, salivary flow may decrease by approximately 50% during the first week of radiotherapy and upwards of 80% by the seventh week of treatment. Acute radiation-induced xerostomia is associated with inflammatory reaction. The study will include an intervention and a control group, one receiving honey prior and after the radiotherapy and the other group not receiving honey at all.

Interventions

DIETARY_SUPPLEMENTHoney mouthwash

The patients in the intervention group will receive honey mouthwash 15 minutes before the radiotherapy session, 15 minutes after and 6 hours after the radiotherapy session

OTHERNormal Saline

Saline rinses 15 minutes before radiotherapy, 15 minutes after, and 6 hours after radiotherapy

Sponsors

Cyprus University of Technology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patients who receive radiotherapy (RT) to the oral cavity will be included in the study. * Patients with a confirmed histologic diagnosis of head and neck cancer referred to non-palliative radiotherapy will enter into this trial. * aged over 18 * receiving radiotherapy for at least four weeks

Exclusion criteria

* Allergic to honey * confirmed and medically treated diabetes mellitus

Design outcomes

Primary

MeasureTime frame
Change from baseline in Xerostomia grades1 week, 2 weeks, 3 weeks, 4 weeks
Change from baseline in oral mucositis grades1 week, 2 weeks, 3 weeks, 4 weeks

Secondary

MeasureTime frame
Changes in the General satisfaction of comfort1 week, 2 week, 3 week, 4 week
Change in baseline weight in one month4 weeks

Countries

Cyprus

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026